First Trust Advisors LP Sells 154,147 Shares of Takeda Pharmaceutical Co. $TAK

First Trust Advisors LP reduced its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 5.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,601,808 shares of the company’s stock after selling 154,147 shares during the period. First Trust Advisors LP’s holdings in Takeda Pharmaceutical were worth $40,224,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Twin Peaks Wealth Advisors LLC bought a new position in shares of Takeda Pharmaceutical in the 2nd quarter valued at about $28,000. Evelyn Partners Investment Management LLP raised its position in Takeda Pharmaceutical by 163.4% during the second quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock valued at $39,000 after purchasing an additional 1,560 shares during the period. NewSquare Capital LLC raised its position in Takeda Pharmaceutical by 182.4% during the second quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock valued at $53,000 after purchasing an additional 2,229 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the last quarter. Finally, MAI Capital Management boosted its holdings in shares of Takeda Pharmaceutical by 212.4% in the 2nd quarter. MAI Capital Management now owns 5,177 shares of the company’s stock worth $80,000 after purchasing an additional 3,520 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 1st. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold”.

Takeda Pharmaceutical Trading Up 0.2%

NYSE TAK opened at $14.26 on Wednesday. The stock has a market cap of $45.36 billion, a PE ratio of 178.19 and a beta of 0.03. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.69. The company’s 50-day moving average price is $14.09 and its 200-day moving average price is $14.62. The company has a current ratio of 1.37, a quick ratio of 0.76 and a debt-to-equity ratio of 0.61.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.44. The company had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.